0001178913-14-002976.txt : 20140918
0001178913-14-002976.hdr.sgml : 20140918
20140918175919
ACCESSION NUMBER: 0001178913-14-002976
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140916
FILED AS OF DATE: 20140918
DATE AS OF CHANGE: 20140918
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: FL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
BUSINESS PHONE: 972-4-988-9488
MAIL ADDRESS:
STREET 1: 2 SNUNIT ST
STREET 2: SCIENCE PARK, POB 455
CITY: CARMIEL
STATE: L3
ZIP: 20100
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bio-Cell Ltd
CENTRAL INDEX KEY: 0001385114
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 141110691
BUSINESS ADDRESS:
STREET 1: MOSHE AVIV TOWER
STREET 2: 7 ZABOTINSKY STREET
CITY: RAMAT GAN
STATE: L3
ZIP: 52520
BUSINESS PHONE: 972-3-611-4514
MAIL ADDRESS:
STREET 1: MOSHE AVIV TOWER
STREET 2: 7 ZABOTINSKY STREET
CITY: RAMAT GAN
STATE: L3
ZIP: 52520
4
1
zk1415562.xml
OWNERSHIP DOCUMENT
X0306
4
2014-09-16
1
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001385114
Bio-Cell Ltd
MOSHE AVIV TOWER
7 ZABOTINSKY STREET
RAMAT GAN
L3
52529
ISRAEL
0
0
1
0
Common Stock
2014-09-16
4
J
0
8556371
D
1509948
I
By Trust
The reporting person, Biocell Ltd., distributed 8,554,988 shares of common stock of Protalix BioTherapeutics, Inc., in a dividend to its shareholders on a pro rata basis based on their respective percentage interests in Biocell Ltd. Biocell Ltd. is an Israeli public company traded on the Tel Aviv Stock Exchange Ltd.
The shares were transferred to the Biocell Ltd. shareholders on a pro rata basis based on their respective percentage interests in Biocell Ltd. No consideration was paid in connection with the transfer.
Substantially all of the shares of Protalix BioTherapeutics, Inc. common stock held by Biocell Ltd. following the dividend reported in this Form 4 are held in a trust for the benefit of Biocell Ltd.
/s/ Zeev Bronfeld
2014-09-18